Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in adults with non-responsive celiac disease
NL-OMON59065Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease and Non-Responsive Celiac Disease (NRCD) comparing Amlitelimab with Placebo (2 arms). Primary endpoint: Change in villus height to crypt depth ratio. Started Aug 2025; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
celiac diseaseNon-Responsive Celiac Disease (NRCD)
Beyond the preview
Go deeper on NL-OMON59065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59065.